Manufacturing Fixed, But Now the FDA Wants Better Data

Atara Biotherapeutics (ATRA) received its second FDA Complete Response Letter for Ebvallo (tabelecleucel) on January 9, 2026, and this one stings differently than the first. The drug is a novel second-line immunotherapy designed to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare but serious condition that can develop after organ transplants.

Here's the twist: Atara actually fixed the problem from the first rejection. The original CRL, issued on January 15, 2025, flagged a single manufacturing compliance deficiency and specifically didn't raise concerns about safety, efficacy, or trial design. So the company went ahead and addressed it.

But in the new letter, the FDA essentially moved the goalposts. The manufacturing issues are resolved, sure, but now the agency says the ALLELE trial — the Phase 3, single-arm, open-label study (NCT03394365) supporting the application — isn't interpretable enough to support accelerated approval.

What the Trial Showed and Why the FDA Changed Its Mind

The ALLELE trial met its prespecified primary efficacy endpoint and showed a generally tolerable safety profile. That's the good news. The bad news is that the FDA now believes the trial design, conduct, and analysis create interpretability issues that make the dataset insufficient for approval.

This isn't about the drug failing or being unsafe. It's about the FDA deciding that the existing evidence, structured the way it was, doesn't meet the bar anymore. Essentially, the agency wants cleaner data with less room for confounding factors — which likely means a randomized or more rigorous confirmatory trial design.

European Approval But American Roadblocks

It's worth noting that Ebvallo has been approved in the European Union since December 16, 2022. So the drug is already being used commercially overseas, but the FDA's standards for accelerated approval appear to have tightened around the existing U.S. submission.

What Happens Next — And Who Pays for It

The most likely path forward involves conducting a new clinical trial to address the FDA's concerns. That's a problem for Atara, which is operating at extremely constrained liquidity levels. The company has already monetized a portion of its Ebvallo EU royalties and certain milestone payments through a royalty-interest transaction with HCRx, meaning it has very few unencumbered assets or cash-flow streams left to sell or finance.

There's a slight cushion here: Pierre Fabre Pharmaceuticals assumed sponsorship of the BLA from Atara in November 2025, so the direct cost burden of a new trial most likely falls on Pierre Fabre. But according to SEC filings, Atara agreed to provide or extend certain services to Pierre Fabre at its own cost, so the company isn't entirely off the hook economically.

If the FDA wants a more credible, less confounded design — think randomized controlled trial instead of single-arm — that could stretch timelines out to two or three years. That's a long time to wait when you're already running on fumes financially.